173 
0 Kommentare
How Viatris Prevents and Manages NCDs
NORTHAMPTON, MA / ACCESS Newswire / October 15, 2025 / NCDs are the leading cause of death globally, representing a significant burden to people and health care systems. As many as 18 million people die annually before the age of 70 from NCDs …
NORTHAMPTON, MA / ACCESS Newswire / October 15, 2025 / NCDs are the leading cause of death globally, representing a significant burden to people and health care systems. As many as 18 million people die annually before the age of 70 from NCDs including cardiovascular disease, cancers, chronic respiratory diseases and diabetes - with a great majority of those deaths happening in low- or lower-middle income countries.1
Viatris' broad portfolio of both off-patent and new, innovative medicines address many NCDs such as cardiovascular disease, diabetes, respiratory diseases, dermatology and ophthalmology. Some examples of our work to expand access across geographies in 2024 include the following:
-
Viatris entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside of the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors.
-
In the U.S., Viatris launched RYZUMVITM (phentolamine ophthalmic solution) for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents. RYZUMVI is the only U.S. commercially available FDA-approved eye drop to reverse dilation.
-
Dymista was successfully launched in China to further improve treatment satisfaction for patients with moderate to severe allergic rhinitis.
-
In seven countries in Europe, Viatris launched Rizmoic (naldemedine tablet), an innovative therapy with a mode of action specifically targeting the underlying cause of opioid-induced constipation.
-
In Canada, Viatris launched PrGlatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RMMS), a chronic inflammatory disease of the central nervous system.
-
In Australia, Relpax Migraine, Dymista Allergy treatments and Celebrex Relief became available to patients without a prescription, offering Australians access to acute treatment options without the need to see an HCP.
Diskutieren Sie über die enthaltenen Werte
URL kopieren
Per E-Mail teilen
Artikel drucken